Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04283669 |
Recruitment Status :
Active, not recruiting
First Posted : February 25, 2020
Last Update Posted : September 11, 2023
|
Sponsor:
University of Alabama at Birmingham
Collaborator:
Memorial Sloan Kettering Cancer Center
Information provided by (Responsible Party):
Bruce Korf, MD, University of Alabama at Birmingham
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | August 18, 2025 |
Estimated Study Completion Date : | December 31, 2025 |